Spirogen Ltd.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Technologies
      • Molecular Diversity
  • Pharmaceuticals
See more in Biomedtracker

Latest on Spirogen Ltd.

Scrip

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By Andy Smith

BioNTech’s acquisition of fellow German mRNA company CureVac underscored a trend in biotech: many companies form around new technologies, but not all succeed. A Very German Transaction BioNTech’s acq

Scrip

ADC’s Phase II Data May Position ‘Lonca’ To Compete With Roche’s Polivy

 
• By Joseph Haas

ADC Therapeutics SARL is aiming to file a biologics license application for its antibody-drug conjugate loncastuximab tesirine (ADCT-402, aka Lonca) in the second half of 2020 following presentation

Scrip

Antibody-Drug Conjugates Attract Hefty Funding To ADC Therapeutics

 
• By John Davis

Having a realistic view of the amount of funding required to take a potential medicine through clinical trials could be thought a prime requirement of a biotech company, one being exhibited by Lausann

Pink Sheet

Deal Watch: NASH In The Hot Seat

 
• By John Davis, Sukaina Virji, and Donna Young

"The Pink Sheet" regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between April 2-1